Related Experiment Video

Updated: Feb 7, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for

Kishan S Parikh1, Kavita Sharma2, Mona Fiuzat1

  • 1Duke Clinical Research Institute, Durham, North Carolina; Duke University School of Medicine, Durham, North Carolina.

JACC. Heart Failure
|August 4, 2018
PubMed

Insights

Heart failure with preserved ejection fraction (HFpEF) affects many, yet critical questions persist. This study summarizes current knowledge, controversies, and research gaps in HFpEF.

Area of Science:

  • Cardiology
  • Clinical Research
  • Translational Science

Background:

  • Heart failure (HF) prevalence is increasing globally.
  • Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of all HF cases.
  • Significant gaps in basic, translational, clinical, and population research hinder HFpEF understanding and management.

Purpose of the Study:

  • To synthesize current knowledge on HFpEF.
  • To identify and discuss persistent controversies in HFpEF research.
  • To highlight critical evidence gaps across the HFpEF research spectrum.

Main Methods:

  • An expert panel "Think Tank" meeting was convened.
  • Participants included representatives from academia, government agencies (NIH, FDA, CMS), and industry.
  • The discussion focused on summarizing existing data and identifying future research needs.

Main Results:

  • Existing knowledge on HFpEF pathophysiology, diagnosis, and treatment is summarized.
  • Key areas of controversy regarding HFpEF mechanisms and therapeutic targets are highlighted.
  • Significant gaps in evidence were identified across basic science, translational studies, clinical trials, and population health research.

Conclusions:

  • Despite rising HFpEF prevalence, substantial knowledge gaps and controversies remain.
  • Further research is urgently needed to advance the understanding and treatment of HFpEF.
  • Multidisciplinary collaboration is essential to address the complexities of HFpEF.

Keywords:
classification schemediagnosisdiastolicejection fractionendpointsheart failurepathophysiologypreserved ejection fractionpulmonary hypertensionsubject eligibilitytreatment

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
604
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
964
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903